Method for monitoring and controlling drug resistance of colorectal cancer patient to panitumumab/cetuximab through ddPCR technology

Abstract

The invention provides a method for monitoring and controlling drug resistance of a colorectal cancer patient to panitumumab / cetuximab through ddPCR technology, and an application of the method to monitoring and controlling of panitumumab / cetuximab in a process of treating colorectal cancer. The method comprises: firstly extracting DNA from peripheral plasma of a colorectal cancer patient, then detecting a mutation situation of a drug-resistant mutation site G13D of KRAS in the DNA through ddPCR technology, and finally judging if the patient produces drug resistance according to the mutation situation.

Description

technical field [0001] The invention relates to the fields of medicine and biotechnology, in particular to a molecular detection technology that can be used to guide tumor treatment, especially a method for highly sensitive detection of the G13D gene mutation at the KRAS gene drug resistance mutation site in peripheral plasma and its role in monitoring colorectal cancer Patients' resistance to panitumumab / cetuximab and other aspects. Background technique [0002] With the development of biomedical technology, molecular targeted drugs have been widely used in the treatment of tumors. Compared with conventional chemotherapy, targeted therapy has the advantages of better effect and less side effects. Clinical application results show that some patients will develop drug resistance to targeted drugs. Research by the American Cancer Society shows that more than 90% of tumor patients are affected by drug resistance to varying degrees during treatment. The drug resistance of tumo...

AI Technical Summary

Problems solved by technology

[0008] However, due to the extremely small amount of plasma cell-free DNA in the blood and the interference of a large amount of blood-derived DNA, it is still difficult to accurately isolate and purify DNA with high-efficiency DNA enrichment methods and high-sensitivity detection methods (such as sequencing, digital PCR). and reliably detect the specific types and sequences of tumor-associated cell-free DNA

For example, it has been reported in the literature that although the average content of circulating cell-free DNA (4771ng / ml) in patients with colorectal cancer is significantly different from that in healthy people (0.85ng / ml), for 67 patients with carcinoembryonic antigen (CEA) Only 47% of the test results are meaningful for diagnosis

[0009] Therefore, although the detection technology based on free blood DNA is the focus of research and development, there is still a lack of satisfactory mutant DNA detection technology in this field that can truly meet the clinical needs of high sensitivity, high accuracy and high reliability.

Images